Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy, immunotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have >= grade adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) before entering the study or those who have not recovered from AEs to ? Grade (except for peripheral neuropathy; see Exclusion Criterion ) due to agents administered more than weeks earlier. Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) or targeted therapies within weeks prior to entering the study or those who have not recovered (=< grade ) from adverse events due to agents administered with the exception of any grade of alopecia Participants who have had any of the following:\r\n* Chemotherapy in the previous weeks ( weeks for nitrosoureas or mitomycin C)\r\n* Radiotherapy within weeks\r\n* Investigational agents within weeks prior to entering the study\r\n* Patients who have not recovered from significant (in the opinion of the investigator) adverse events due to previous agents administered Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Subjects who have had chemotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study (e.g. start of study treatment), or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C), small molecule targeted therapy (i.e. kinase inhibitors) within weeks or the last dose of antibody therapy within weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Subject who has had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Chemotherapy or radiotherapy within week ( weeks for nitroureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Those who have had chemotherapy or radiotherapy or targeted agents within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy within weeks or five half-lives, whichever is shorter, ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier; steroids for symptom palliation are allowed, but must be either discontinued or on stable doses at the time of initiation of protocol therapy Prior chemotherapy or radiation within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Exposure to chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Use of any other chemotherapy, radiotherapy, or experimental drug or therapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to enrollment on study or those who have not recovered from adverse events >= grade due to agents administered more than weeks earlier except for stable grade neuropathy Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier; corticosteroid treatment is allowed Patients who have had chemotherapy within weeks ( weeks for nitrosoureas or mitomycin C) of study drug administration or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy/radiotherapy and/or targeted agents within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier; the washout chemotherapy/radiotherapy and/or target agents for these patients will be at the investigators discretion. Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to starting study treatment or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had radiotherapy or chemotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosourea or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C, half-lives for targeted therapies) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier; concurrent palliative radiotherapy is allowed at the discretion of the treating physician Subjects who have had immunotherapy, chemotherapy, or radiation therapy within days ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier; patients who have had targeted therapy will be required to wait weeks due to short half-life of the drugs; treatment with bisphosphonates is permitted Prior chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy within weeks ( weeks for nitrosoureas or mitomycin C) or radiotherapy within weeks for antecedent malignancies prior to entering the study, or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier (e.g. alopecia, hypothyroid, neuropathy, etc.) Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C, or monoclonal antibodies such as bevacizumab, cetuximab or panitumumab) prior to entering the study or those who have not recovered to =< grade adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered to =< grade adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had treatment with chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to starting study treatment or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier are excluded; this does not include the use of steroids which may continue until two days prior to enrollment Participants who have had chemotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to study entry or those with adverse events due to agents administered more than weeks earlier that have not resolved to =< grade per Common Terminology Criteria for Adverse Events (CTCAE) version (v.) Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier; participants who have been treated with a tyrosine kinase inhibitor within days Previously treated with irinotecan, or had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study, or not recovered from adverse effects due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to study enrollment or those who have not recovered from adverse events due to agents administered more than weeks prior to study enrollment Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier; patients may have received dexamethasone within weeks prior to entering study Participants who have had chemotherapy, targeted small molecule therapy, or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier; in addition, no small molecule kinase inhibitors or any other type of investigational agent may have been administered within weeks before first dose of study treatment Chemotherapy, radiotherapy or hormonal therapy within weeks ( weeks for nitrosoureas, mitomycin C or bevacizumab), or who have not recovered from the adverse events to < grade due to previous agents administered more than weeks prior to study day Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within days ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier; patients who have had prior treatment with any PARP inhibitors are ineligible Patients who have had cytotoxic chemotherapy, radiotherapy, interferon (IFN), immunosuppressive therapy, or steroids within weeks ( weeks for nitrosoureas or mitomycin C) before entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier (with the exception of alopecia and neuropathy); no radiation is allowed on study Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Prior systemic chemotherapy for anaplastic thyroid cancer\r\n* Patients who have had chemotherapy or radiotherapy within weeks of registration ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered > weeks previously\r\n* Patients receiving other investigational agents Patient who has had chemotherapy, radiotherapy, or biological therapy, within days ( days for nitrosoureas or mitomycin C) or who has not recovered from adverse events due to agents administered more than days earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events to =< grade due to agents administered more than weeks earlier; for investigational targeted therapies patients will need to clear for half lives (not applicable to standard of care therapies) Patients who have had chemotherapy within weeks ( weeks for nitrosoureas or mitomycin C) of study drug administration or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C, weeks for rituximab) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Receipt of chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Chemotherapy, within weeks prior to entering the study ( weeks for nitrosoureas or mitomycin) or those who have not recovered to less than or equal to grade from adverse events due to agents administered more than weeks earlier Participants may not have had chemotherapy or radiation therapy (RT) within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study and must have recovered to =< grade from adverse events due to agents administered more than weeks earlier; patients should not have received hormonal therapy for treatment of their cancer within weeks of study entry Patients who have had targeted therapy, chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy, radiotherapy, experimental therapy or major surgery within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered (to grade =< or baseline) from clinically significant adverse events due to agents administered more than weeks earlier (alopecia and fatigue excluded); clinical significance to be determined by investigator Participants who have had any prior systemic therapy for CLL, or chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) for some other indication prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy within weeks ( weeks for nitrosoureas or mitomycin C) or radiation therapy within weeks prior to entering the study or those who have not recovered to =< grade (except alopecia) from adverse events (as per the revised NCI CTCAE version ) due to agents administered more than weeks earlier Patients who have had chemotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patient has had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas, anti-angiogenic agents, or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had anti-VEGFR tyrosine kinase inhibitor within week, mTOR inhibitor within week or anti-VEGF antibody therapy within weeks prior to entering the study; patients who have had other forms of chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to day or those who have not recovered from adverse events (AEs) due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Use of any other chemotherapy, radiotherapy, or experimental drug or therapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to enrollment on study or those who have not recovered from adverse events =< grade due to agents administered more than weeks earlier except for stable grade neuropathy Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier; current treatment with leuprolide or other gonadotropin-releasing hormone (GnRH) agonists is permitted on the Phase I portion of the study EXPANSION COHORT ONLY: Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy =< weeks ( weeks for nitrosoureas or mitomycin C) prior to registration or those who have not recovered from adverse events due to agents administered >= weeks earlier; patients may not be receiving any other investigational agents Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for radiotherapy to the lung fields and weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered to =< grade (or =< tolerable grade for neuropathy) adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier to grade or below (unless approved by the study chair) Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Subject who has had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from prior treatment related toxicity with persistent symptoms >/= grade due to agents administered more than weeks earlier. Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy within weeks ( weeks for nitrosoureas or mitomycin C), or radiotherapy within weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (CTCAE Grade > ) due to agents administered more than weeks earlier. Patients who have had chemotherapy or radiotherapy within days ( weeks for nitrosoureas or mitomycin C) prior to study screening or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy (non-tyrosine kinase inhibitor [TKI]) or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Chemotherapy, radiotherapy, or surgery within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (toxicities not improved to =< grade ) due to agents administered more than weeks earlier; additionally, patients experiencing disease progression within months of platinum-based therapy will be excluded from trial participation Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy or targeted agents within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier will be excluded Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier Participants who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than weeks earlier